B.Braun Patent-Cliff Exposure & CMS Drug Spending Portfolio

B.Braun (US): 13 reconciled FDA prescription therapies, $37.8M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies13
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$37.8M
2024 Medicare Part D Spend$5.1M
2024 Medicaid Spend$32.8M
California HCAI SB 17 Filings5 WAC filings (max 26.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for B. Braun Medical across sibling Meru public-data platforms.